Clinical Trial Update: The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updating pharmacokinetics and safety of IDV/r with NRTIs in HIV/TB co-infected patients on rifampicin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• IDV/r (idarucazide/ritonavir)

Snippet

Sponsor: The HIV Netherlands Australia Thailand Research Collaboration | Conditions: HIV Infections, Tuberculosis | Phase 1, Phase 2 | Status: COMPLETED